all included studies with significant heterogeneity (I 2 = 99%, P < 0.00) [ Figure 5 ].
Results of studies administered systemic statins
Fajardo et al. [10] in their RCT gave atorvastatin (20 mg) or placebo daily for 3 months and observed improvement in both groups. After comparing, significant improvements were observed in IBD -0.75 ± 0.7 versus 0.09 ± 0.4 mm, P = 0.0006 in the atorvastatin group.
Subramanian et al. [19] in RCT conducted on 83 patients compared 80 mg atorvastatin with 10 mg atorvastatin observed that high-dose atorvastatin is associated with a reduction in periodontal inflammation at 12-week follow-up. None of these two studies had reported any side effect or adverse effect of statins during the study period and observed that the oral drug is well tolerated.
dIscussIon
The primary goal of periodontal therapy is regeneration of lost periodontal support. Untreated periodontal diseases may result in destruction of tooth supporting structures. Various cost-effective material/molecules are being evaluated for safety and efficiency to promote periodontal regeneration in recent years. Apart from lipid lowering action, statins have pleiotropic effects such as anti-inflammatory, antioxidant and anabolic effects on bone. [20] To assess the therapeutic benefits of statins in periodontitis, only RCTs were included in the present systematic review and meta-analysis. The present meta-analysis was aimed at assessing effect of systemic or local statin on clinical as well as radiographic periodontal parameters in patients with chronic periodontitis.
In a multicentric double-blind trial, high-dose atorvastatin is associated with a reduction in periodontal inflammation. The impact of statins was greatest in active periodontitis patients and was evident after a 4-week treatment period. [9] A well-conducted RCT included in this systematic review concluded that systemic administration on 20 mg atorvastatins is an effective therapeutic device in the management of periodontal disease, due to its beneficial effect on alveolar bone metabolism compared to placebo. [10] Only these two evidence has evaluated systemic administration of atorvaststin and one [19] of these has not evaluated any clinical periodontal parameter while other [10] has just evaluated distance from cementoenamel junction to alveolar crest. These studies were excluded from meta-analysis.
Local stimulation of BMP-2 can lead to new bone formation. Mundy et al. identified that four different statins (i.e., lovastatin, simvastatin, mevastatin and fluvastatin) has increased gene expression for BMP-2 in osteoblasts. [13] A systematically performed literature review by Sophia [21] also has observed that statins have a broad therapeutic effects and promising in regenerative therapies. The results of the present meta-analysis also suggested that statins have beneficial effects on the periodontitis if given systemically for short-term as well as delivered locally.
Estanislau et al. [22] in a systematic review support the same with the observation that indicate statins have beneficial effects by stimulating bone formation, decreasing inflammation and immunomodulation.
Summary of main results
Reduction in IBD and gain in CAL are the primary outcomes to determine success of regenerative periodontal therapy. All the included RCTs performed the statistical analysis and compared the IBD and CAL. They observed statistically significant difference for both. The meta-analysis showed SMD for reduction in IBD1.90 mm (1.46-2.35) and gain in CAL was found to be 1.94 mm (1.07, 2.81).
Statins show beneficial effect systemically as well as locally but cannot substitute for the standard periodontal treatment, which consists of mechanical debridement as local deposits are considered to be the primary aetiologic factor of the disease.
Limitations of the present systematic review and meta-analysis
One of the primary limitations of this analysis is that reviewers were not able to procure any unpublished data or data from any ongoing trials. The majority of the included trials were conducted in single institute which can affect its generalisability to global population.
conclusIon
There are very few studies on applicability of statins in chronic periodontitis in the literature, but results of this meta-analysis indicate that statins hold beneficial effects. This suggests that this group of drugs might have a great potential to improve the outcomes in the treatment of periodontitis since they are safe and not costly. However, they cannot substitute the standard periodontal treatment, which consists of removing microorganisms, considered to be the primary aetiologic factor of the disease. This systematic review and meta-analysis of current evidence of has confirmed the benefits of using statins compared to placebo. This showed a standardised mean difference of 1.94 mm in CAL (1.07, 2.81) and 1.91 mm for IBD (1.46, 2.35) after treatment of IBDs with statins.
Clinical implications
This analysis showed statistically as well as clinically significant improvements in the clinical and radiographic periodontal parameters such as CAL, IBD, reduction in PD and SBI were treated with statins. As statins are effective and safe in short-term use and locally delivered and user-friendly, they can be more widely used in periodontal treatment.
Implications for future research
Local as well as systemic statins can be a cost-effective treatment alternative for periodontitis where its efficacy can be evaluated in large multicentred trials and various other indications in periodontology as well as implant dentistry. Local statin therapy with various controlled release system can be evaluated for maximum benefits. Long-term benefits and safety of the same also need to be evaluated.
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references IntroductIon
Entanglement of umbilical cord around the foetal neck (nuchal cord) is a common finding at delivery. It is often assumed that nuchal cord causes cord compression and thus low birth weight and intra-partum complications. The assumption that nuchal cord entanglement could cause cord compression and thus intra-partum complication is not recent. About 20%-60% of all foetal deaths are attributed to foetal asphyxia. However, aetiology in all cases of foetal asphyxia is not exactly understood. Asphyxia is most frequently seen as a result of reduced placental circulation, but in rare cases, it might develop secondary to umbilical cord complications. Nuchal cord accident comprises 5%-18% of all foetal asphyxia cases, and 10% of stillbirth were due to umbilical cord complications. [1, 2] A nuchal cord occurs when the umbilical cord becomes wrapped around the foetal neck 360°. [3] Nuchal cord is very common, with the prevalence rates of 6%-37%. Up to half of nuchal cords resolve before delivery. [4] The umbilical cord is a narrow tube-like structure that connects the developing baby to the placenta. The cord is sometimes called the baby's 'supply line' because it carries the baby's blood back and forth, between the baby and the placenta. It delivers nutrients and oxygen to the baby and removes the baby's waste products. The umbilical cord begins to form at 5 weeks after conception. It becomes progressively longer until 28 weeks of pregnancy, reaching an average length of 22-24 inches. [5] As the cord gets longer, it generally coils around itself. The cord contains three blood vessels: two arteries and one vein.
In some cases, cord abnormalities are discovered before delivery during an ultrasound (USG). However, they usually
